Business
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a suite of powerful advancements that will significantly accelerate the next era of genomic discovery. Unveiled at the Advances in Genome Biology and Technology (AGBT) 2026 conference, the announcements include the launch of TruPath™ Genome, a new standard in genomic insight; a groundbreaking roadmap for the NovaSeq X Series; and new partner-driven cancer breakthroughs powered by Illumin
About this update from Illumina, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers ","length":271,"tagName":"p"}]},{"val":[{"type":"text","content":"At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions ","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":551,"olType":false},{"type":"text","content":"SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a suite of powerful advancements that will significantly accelerate the next era of genomic discovery. Unveiled at the Advances in Genome Biology and Technology (AGBT) 2026 conference, the announcements include the launch of TruPath™ Genome, a new standard in genomic insight; a groundbreaking roadmap for the NovaSeq X Series; and new partner-driven cancer breakthroughs powered by Illumina's spatial and multiomic technologies.","length":584,"tagName":"p"},{"type":"text","content":"TruPath Genome, a new standard in genomic insight","length":49,"tagName":"p"},{"type":"text","content":"Illumina's launch of TruPath™ Genome sets a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution – even across so-called "dark regions" of the genome – providing researchers with a more complete picture of genomic alterations implicated in genetic disease.","length":388,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Illumina)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Illumina)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/7e74c44d68bacbe76a244d57c28cf1ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3CEz_pP._zaAxL7.oOWHTA--/YXBwaW...